Causes & Triggers


While the cause of rosacea is not known, some risk factors (characteristics that identify a person as more likely to develop rosacea) have been identified. One of the risk factors of rosacea is skin type. People with fair or light-colored skin, blonde or red hair and blue or green eyes are more susceptible to rosacea. Also, rosacea also has a "hereditary" component, which simply means that rosacea tends to run in families.


Certain environmental factors, known as "triggers", can cause flare-ups and worsening of rosacea symptoms.

Triggers can be found everywhere. Certain foods, beverages, cosmetics, changes in temperature and humidity, wind, emotional stress - these are just some of the things that may trigger a rosacea flare-up. What's more, triggers vary from one person to the next. One person may need to avoid chocolate entirely or risk a bad flare-up, while another can eat chocolate but not cheese. Still another person may enjoy both, but start flushing after a few sips of hot coffee.

While medication is an essential part of symptom management for most rosacea patients, learning to identify and avoid triggers is also important. You can find out more about triggers by visiting the Food & Drink, Lifestyle and Tracking pages of this website.

Finacea® (azelaic acid) Gel, 15% is indicated for topical treatment of inflammatory papules and pustules of mild to moderate rosacea.

Although some reduction of erythema which was present in patients with papules and pustules of rosacea occurred in clinical studies, efficacy for treatment of erythema in rosacea in the absence of papules and pustules has not been evaluated.

There have been isolated reports of hypopigmentation after use of azelaic acid. Since azelaic acid has not been well studied in patients with dark complexion, these patients should be monitored for early signs of hypopigmentation. Finacea® and its vehicle caused irritant reactions at the application site in human dermal safety studies. Skin irritation (e.g. pruritus, burning or stinging) may occur during use with Finacea®, usually during the first few weeks of treatment. If sensitivity or severe irritation develops and/or persists during use with Finacea®, discontinue use and institute appropriate therapy.

In clinical trials with Finacea®, the most common local adverse events (AE's) were: burning/stinging/tingling (29%), pruritus (11%), scaling/dry skin/xerosis (8%) and erythema/irritation (4%). Contact dermatitis, edema and acne were observed at frequencies of 1% or less. Rarely reported AE's included: worsening of asthma, vitiligo depigmentation, small depigmented spots, hypertrichosis, reddening (signs of keratosis pilaris) and exacerbation of recurrent herpes labialis. Post-marketing safety information: Skin (facial burning and irritation); Eyes (iridocyclitis on accidental exposure with Finacea® to the eye). To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare at 1-866-463-3634 or FDA at 1-800-FDA-1088 or

Finacea® is for topical use only. It is not for ophthalmic, oral or intravaginal use. In case of accidental eye exposure, wash eyes with large amounts of water and consult a physician if eye irritation persists. Wash hands following application of Finacea®.

See Full Prescribing Information for Finacea® at

Click here to return to

You are about to leave Are you sure you want to leave?